While this could potentially be a source of bias, we included only those patients who fulfilled clinical diagnostic criteria in combination with other objective markers, i.e., CSF biomarkers in AD and dopamine transporter imaging in DLB. The gene discussed is SLC6A3; the disease is Alzheimer disease.